Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2021 17:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Receives Final Court Order Approving Arrangement

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
October 26, 2021 17:15 ET | Source: Trillium Therapeutics Inc.

Trillium Securityholders Approve Acquisition by Pfizer

CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
August 23, 2021 06:45 ET | Source: Trillium Therapeutics Inc.

Pfizer to Acquire Trillium Therapeutics Inc.

Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative...
August 13, 2021 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results

CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
August 09, 2021 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia

CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
July 06, 2021 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
June 30, 2021 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
June 29, 2021 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma

CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
June 25, 2021 18:28 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Joins Russell 2000® and 3000® Indices

CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
June 09, 2021 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for...